ASND

Insider trade Purchase by BIENAIME JEAN JACQUES

19h ago

Insider trade Purchase by SMITH SCOTT THOMAS (EVP & Chief Financial Officer)

19h ago

Insider trade Purchase by BIENAIME JEAN JACQUES

5d ago

News Ionis, Alnylam, BioMarin up as Citi starts at Buy on catalyst and growth outlook

13d ago

News BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026

14d ago

News Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug

14d ago

News Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year

14d ago

News Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?

14d ago

News BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish

14d ago

Insider trade Sale by Flemming Steen Jensen (EVP & Product Supply and Quality)

20d ago

SEC filing ASND Reports €247M Q1 Rev, €197M YORVIPATH Rev, €44M SKYTROFA Rev, +146% YoY Rev, +94% YoY Net Income, +1,000+ New Patients, $187.5M RPU Sale

26d ago

SEC filing ASND Reports $1.2B Revenue, $0.45 EPS, Announces $500M Share Buyback

26d ago

News Ascendis Pharma A/S Q1 2026 Earnings Preview

27d ago

SEC filing ASND Reports $1.2B Revenue, $0.45 EPS, +28% YoY Growth, Announces $500M Share Buyback

41d ago

SEC filing ASND Reports $1.2B Revenue, $0.45 EPS, +18% YoY Growth, Announces $500M Share Buyback

43d ago

SEC filing ASND Reports $0 Revenue, $0 EPS, 0% Growth, 0 Shares Voted for Chairman, 0% Approval for Auditor, 0% Profit Carryforward, 0% Board Reelection, 0% Share Buyback Authorization

69d ago

SEC filing ASND Reports $1.2B Revenue, $0.45 EPS, Announces $300M Debt Offering

77d ago

News Ascendis Pharma wins FDA approval for navepegritide for achondroplasia

94d ago

Short volume Short volume 84% of volume (3.7σ)

124d ago

News Ascendis Pharma rises amid takeover speculation

131d ago